Quantcast

Industry news that matters to you.  Learn more

Aushon BioSystems Forms Scientific Advisory Board

Aushon BioSystems, Inc., a leading provider of advanced microarray products and laboratory services for biomarker discovery, development and analysis, announced today the formation of a Scientific Advisory Board consisting of internationally renowned physicians and scientists at the forefront of applying biomarker technology in clinical drug development.

CompanDx Launches Biomarker Panel for Predicting Time to Breast Cancer Metastasis

U.K.-based biomarker discovery services firm Compandia has changed its name to CompanDx and launched a 31 gene breast cancer metastasis prediction panel it calls Time to an Event. Developed using the company’s Risk Distiller bioinformatics tool, the Time to an Event biomarker panel can accurately predict time to metastasis following initial surgery and biopsy, CompanDx claims. The firm says it is now applying for funding to further validate the panel in the clinic. It already has collaborations in place with leading clinical centers, and industry support has been secured with a major diagnostics company.

Improvement in Prediction of Blood Clots in Cancer Patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

$9.1 Million Grant To Improve Drug Therapy Using Gene Profiles

The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled “Expression Genetics in Drug Therapy.” The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

Plavix Biomarker Test Can Improve Patient Outcomes

In January, the Agency for Healthcare Research and Quality (AHRQ) released “Outpatient Prescription Anticoagulants Utilization and Expenditures for the U.S. Civilian Noninstitutionalized Population Age 18 and Older 2007,” a study from its October 2009 Medical Expenditure Panel Survey (MEPS). This report found that anticoagulant drugs were prescribed to more than 4.2 million Americans at a cost of $900 million and were paid for by patients and/or third-party payers.